// Dupixent (Sanofi - Immunology) Regulatory Rules for Glocalization
// Source Market: US | Target Markets: Germany, France, China

export const DupixentRegulatoryRules = [
  // ============================================================
  // US → GERMANY (DE) - 30 Rules
  // ============================================================
  
  // MUST_CHANGE Rules (10)
  {
    id: 'dup-us-de-must-001',
    ruleId: 'REG_BODY_REPLACEMENT',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Regulatory Authority',
    description: 'Replace FDA with EMA and BfArM',
    rationale: 'German market operates under European Medicines Agency (EMA) and German Federal Institute for Drugs and Medical Devices (BfArM) jurisdiction',
    exampleBefore: 'FDA-approved for moderate-to-severe atopic dermatitis',
    exampleAfter: 'EMA/BfArM-zugelassen für mittelschwere bis schwere atopische Dermatitis',
    regulatoryReference: 'EMA/H/C/004390 | BfArM',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-must-002',
    ruleId: 'MEDICAL_TERMINOLOGY_TRANSLATION',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Language & Terminology',
    description: 'Translate all medical terminology to German',
    rationale: 'German healthcare professionals require precise medical terminology in German language',
    exampleBefore: 'Moderate-to-severe atopic dermatitis',
    exampleAfter: 'Mittelschwere bis schwere atopische Dermatitis',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-must-003',
    ruleId: 'CONTACT_INFO_LOCALIZATION',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Contact Information',
    description: 'Replace US contact information with German medical information hotline',
    rationale: 'German healthcare professionals need local language support and German regulatory contact',
    exampleBefore: 'For Medical Information: 1-800-DUPIXENT',
    exampleAfter: 'Für medizinische Informationen: +49 (0) 69 305 7087',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-must-004',
    ruleId: 'CLINICAL_TRIAL_REFERENCES',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Clinical Evidence',
    description: 'Update clinical trial references to include European studies',
    rationale: 'German regulatory requirements emphasize European clinical data and EudraCT registration',
    exampleBefore: 'Based on pivotal US trials (SOLO 1, SOLO 2)',
    exampleAfter: 'Basierend auf zulassungsrelevanten europäischen Studien (SOLO 1, SOLO 2, CHRONOS)',
    regulatoryReference: 'EudraCT database references',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-must-005',
    ruleId: 'DATE_FORMAT_CHANGE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Formatting Standards',
    description: 'Change date format from MM/DD/YYYY to DD.MM.YYYY',
    rationale: 'German standard date format uses DD.MM.YYYY (day.month.year)',
    exampleBefore: '03/15/2024',
    exampleAfter: '15.03.2024',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-must-006',
    ruleId: 'PRESCRIBING_INFO_REPLACEMENT',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Regulatory Documentation',
    description: 'Replace US Prescribing Information with German Fachinformation',
    rationale: 'German market requires Fachinformation (SmPC equivalent) instead of US PI',
    exampleBefore: 'See Full Prescribing Information',
    exampleAfter: 'Siehe vollständige Fachinformation',
    regulatoryReference: 'BfArM Fachinformation requirements',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-must-007',
    ruleId: 'PHARMACOVIGILANCE_UPDATE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Safety Reporting',
    description: 'Update adverse event reporting procedures for German pharmacovigilance',
    rationale: 'Germany follows EMA pharmacovigilance system and BfArM reporting requirements',
    exampleBefore: 'Report adverse events to FDA at 1-800-FDA-1088',
    exampleAfter: 'Meldung von Nebenwirkungen an BfArM oder EMA',
    regulatoryReference: 'BfArM UAW-Meldung requirements',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-must-008',
    ruleId: 'PROFESSIONAL_SOCIETIES',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Professional References',
    description: 'Include references to German dermatology and allergy societies',
    rationale: 'German healthcare system values endorsements from DDG (German Dermatological Society) and DGAKI (German Allergy Society)',
    exampleBefore: 'Recommended by American Academy of Dermatology',
    exampleAfter: 'Empfohlen gemäß Leitlinien der DDG (Deutsche Dermatologische Gesellschaft)',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-must-009',
    ruleId: 'WEBSITE_DOMAIN_UPDATE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Digital Presence',
    description: 'Replace US website URLs with German .de domain',
    rationale: 'German healthcare professionals expect localized German-language website',
    exampleBefore: 'Visit www.dupixent.com',
    exampleAfter: 'Besuchen Sie www.dupixent.de',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-must-010',
    ruleId: 'REIMBURSEMENT_LANGUAGE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Healthcare System',
    description: 'Update reimbursement language for German health insurance (GKV)',
    rationale: 'German healthcare system operates on statutory health insurance (GKV) model with specific reimbursement processes',
    exampleBefore: 'Covered by most US insurance plans',
    exampleAfter: 'Erstattungsfähig im Rahmen der GKV nach individuellem Therapieplan',
    therapeuticArea: 'Immunology'
  },

  // CANNOT_CHANGE Rules (10)
  {
    id: 'dup-us-de-cannot-001',
    ruleId: 'MECHANISM_OF_ACTION',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Mechanism of Action',
    description: 'IL-4 and IL-13 dual pathway inhibition mechanism',
    rationale: 'Core mechanism of action is scientifically established and cannot be altered for different markets',
    exampleBefore: 'Dupilumab inhibits IL-4 and IL-13 signaling',
    exampleAfter: 'Dupilumab inhibiert IL-4- und IL-13-Signalwege (translation only, not modification)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-cannot-002',
    ruleId: 'PRIMARY_INDICATION',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Approved Indication',
    description: 'Moderate-to-severe atopic dermatitis indication',
    rationale: 'EMA-approved indication is identical to FDA approval for this condition',
    exampleBefore: 'Indicated for moderate-to-severe atopic dermatitis',
    exampleAfter: 'Zugelassen für mittelschwere bis schwere atopische Dermatitis (same indication, translated)',
    regulatoryReference: 'EMA/H/C/004390',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-cannot-003',
    ruleId: 'STANDARD_DOSING',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Dosing',
    description: 'Standard adult dosing regimen (600mg loading, 300mg Q2W)',
    rationale: 'Approved dosing regimen is identical across FDA and EMA labels',
    exampleBefore: '600mg loading dose, then 300mg every 2 weeks',
    exampleAfter: '600mg Initialdosis, dann 300mg alle 2 Wochen (same dosing, translated)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-cannot-004',
    ruleId: 'CLINICAL_EFFICACY_DATA',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Clinical Evidence',
    description: 'Pivotal trial efficacy outcomes (EASI-75, IGA 0/1)',
    rationale: 'Clinical trial endpoints and results are scientifically validated and cannot be altered',
    exampleBefore: 'EASI-75 achieved in 51% of patients (SOLO 1)',
    exampleAfter: 'EASI-75 bei 51% der Patienten erreicht (SOLO 1) (same data, translated)',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-cannot-005',
    ruleId: 'ADVERSE_EVENT_PROFILE',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Safety Profile',
    description: 'Core adverse event profile (injection site reactions, conjunctivitis)',
    rationale: 'Safety data from clinical trials is universal and scientifically documented',
    exampleBefore: 'Most common: injection site reactions (10%), conjunctivitis (10%)',
    exampleAfter: 'Häufigste Nebenwirkungen: Reaktionen an der Injektionsstelle (10%), Konjunktivitis (10%) (same data, translated)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-cannot-006',
    ruleId: 'CONTRAINDICATIONS',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Contraindications',
    description: 'Hypersensitivity to dupilumab or excipients',
    rationale: 'Contraindications are medically absolute and apply universally',
    exampleBefore: 'Contraindicated in patients with hypersensitivity to dupilumab',
    exampleAfter: 'Kontraindiziert bei Überempfindlichkeit gegen Dupilumab (same contraindication, translated)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-cannot-007',
    ruleId: 'BIOMARKER_MONITORING',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Monitoring Requirements',
    description: 'Eosinophil count monitoring recommendations',
    rationale: 'Clinical monitoring parameters are based on safety data and apply globally',
    exampleBefore: 'Monitor eosinophil counts in asthma patients',
    exampleAfter: 'Überwachung der Eosinophilenzahlen bei Asthma-Patienten (same requirement, translated)',
    therapeuticArea: 'Immunology',
    indication: 'Asthma'
  },
  {
    id: 'dup-us-de-cannot-008',
    ruleId: 'DRUG_INTERACTIONS',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Drug Interactions',
    description: 'Lack of significant drug-drug interactions',
    rationale: 'Pharmacokinetic interaction data is scientifically established',
    exampleBefore: 'No clinically significant drug interactions identified',
    exampleAfter: 'Keine klinisch relevanten Arzneimittelwechselwirkungen identifiziert (same data, translated)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-cannot-009',
    ruleId: 'PREGNANCY_CATEGORY',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Special Populations',
    description: 'Pregnancy and lactation safety data',
    rationale: 'Limited pregnancy data requires consistent safety messaging globally',
    exampleBefore: 'Limited data in pregnant women; use only if clearly needed',
    exampleAfter: 'Begrenzte Daten bei Schwangeren; nur anwenden wenn eindeutig erforderlich (same guidance, translated)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-cannot-010',
    ruleId: 'MOLECULAR_STRUCTURE',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Pharmacology',
    description: 'Molecular structure and monoclonal antibody classification',
    rationale: 'Chemical structure and drug classification are universal scientific facts',
    exampleBefore: 'Dupilumab is a fully human monoclonal antibody (IgG4)',
    exampleAfter: 'Dupilumab ist ein vollständig humaner monoklonaler Antikörper (IgG4) (same structure, translated)',
    therapeuticArea: 'Immunology'
  },

  // SHOULD_CHANGE Rules (10)
  {
    id: 'dup-us-de-should-001',
    ruleId: 'FORMAL_COMMUNICATION',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Communication Tone',
    description: 'Use formal German "Sie" form, not informal "Du"',
    rationale: 'German medical communication requires formal address for professional credibility',
    exampleBefore: 'Talk to your doctor',
    exampleAfter: 'Sprechen Sie mit Ihrem Arzt (formal Sie, not Du)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-002',
    ruleId: 'EVIDENCE_BASED_EMPHASIS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Medical Culture',
    description: 'Emphasize evidence-based medicine and clinical guidelines',
    rationale: 'German medical culture highly values evidence hierarchy and guideline-based treatment',
    exampleBefore: 'Proven effective in clinical trials',
    exampleAfter: 'Wirksamkeit belegt durch evidenzbasierte klinische Studien gemäß DDG-Leitlinien',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-003',
    ruleId: 'BIOLOGICS_EXPERTISE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Treatment Context',
    description: 'Reference German biologics treatment pathways and specialist requirements',
    rationale: 'Germany has specific requirements for biologics initiation and dermatology specialist oversight',
    exampleBefore: 'Available by prescription',
    exampleAfter: 'Verordnung durch Dermatologen mit Biologika-Erfahrung erforderlich',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-004',
    ruleId: 'QUALITY_OF_LIFE_MEASURES',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Patient Outcomes',
    description: 'Use German-validated quality of life instruments (DLQI)',
    rationale: 'German healthcare emphasizes validated German QoL measures in dermatology',
    exampleBefore: 'Improves patient quality of life',
    exampleAfter: 'Verbesserung der Lebensqualität (gemessen durch DLQI)',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-de-should-005',
    ruleId: 'PATIENT_SUPPORT_PROGRAMS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Patient Services',
    description: 'Adapt patient support program language for German healthcare context',
    rationale: 'German patient support programs operate differently from US programs',
    exampleBefore: 'MyDupixent patient support program',
    exampleAfter: 'Dupixent-Patientenunterstützungsprogramm mit Schulung zur Selbstinjektion',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-006',
    ruleId: 'MULTIDISCIPLINARY_CARE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Care Delivery',
    description: 'Emphasize multidisciplinary dermatology-allergy collaboration',
    rationale: 'German healthcare system values interdisciplinary care between dermatologists and allergists',
    exampleBefore: 'Consult your dermatologist',
    exampleAfter: 'Interdisziplinäre Betreuung durch Dermatologen und Allergologen empfohlen',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-007',
    ruleId: 'LONG_TERM_THERAPY_EMPHASIS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Treatment Duration',
    description: 'Emphasize long-term disease control and sustained efficacy',
    rationale: 'German reimbursement and medical culture focus on long-term therapeutic value',
    exampleBefore: 'Rapid symptom improvement',
    exampleAfter: 'Nachhaltige Krankheitskontrolle über 52 Wochen (Langzeitwirksamkeit)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-008',
    ruleId: 'IMMUNIZATION_GUIDANCE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Preventive Care',
    description: 'Include German immunization recommendations for biologics patients',
    rationale: 'German infectious disease guidelines (STIKO) have specific recommendations for biologics',
    exampleBefore: 'Discuss vaccinations with your doctor',
    exampleAfter: 'Impfstatus gemäß STIKO-Empfehlungen vor Therapiebeginn prüfen',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-009',
    ruleId: 'COST_EFFECTIVENESS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Health Economics',
    description: 'Include health economic value and cost-effectiveness data',
    rationale: 'German healthcare system (IQWiG assessments) values cost-effectiveness evidence',
    exampleBefore: 'Effective treatment option',
    exampleAfter: 'Kosteneffektive Therapieoption mit positiver IQWiG-Nutzenbewertung',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-de-should-010',
    ruleId: 'PEDIATRIC_EXPERIENCE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'Germany',
    category: 'Pediatric Use',
    description: 'Emphasize pediatric atopic dermatitis data and German pediatric dermatology societies',
    rationale: 'Germany has strong pediatric dermatology subspecialty and specific guidelines',
    exampleBefore: 'Approved for ages 6 and up',
    exampleAfter: 'Zugelassen ab 6 Jahren mit umfangreichen pädiatrischen Daten gemäß DGKJ-Leitlinien',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },

  // ============================================================
  // US → FRANCE (FR) - 30 Rules (10 MUST + 10 CANNOT + 10 SHOULD)
  // ============================================================
  
  // MUST_CHANGE Rules (10)
  {
    id: 'dup-us-fr-must-001',
    ruleId: 'REG_BODY_REPLACEMENT',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Regulatory Authority',
    description: 'Replace FDA with EMA and ANSM',
    rationale: 'France operates under EMA approval with ANSM national oversight',
    exampleBefore: 'FDA-approved for moderate-to-severe atopic dermatitis',
    exampleAfter: 'Approuvé par l\'EMA/ANSM pour la dermatite atopique modérée à sévère',
    regulatoryReference: 'EMA/H/C/004390 | ANSM',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-fr-must-002',
    ruleId: 'MEDICAL_TERMINOLOGY_TRANSLATION',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Language & Terminology',
    description: 'Translate all medical terminology to French',
    rationale: 'French healthcare professionals require precise medical terminology in French',
    exampleBefore: 'Moderate-to-severe atopic dermatitis',
    exampleAfter: 'Dermatite atopique modérée à sévère',
    therapeuticArea: 'Immunology',
    indication: 'Atopic Dermatitis'
  },
  {
    id: 'dup-us-fr-must-003',
    ruleId: 'CONTACT_INFO_LOCALIZATION',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Contact Information',
    description: 'Replace US contact information with French medical information hotline',
    rationale: 'French healthcare professionals need local French support',
    exampleBefore: 'For Medical Information: 1-800-DUPIXENT',
    exampleAfter: 'Information médicale: 01 57 37 36 00',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-004',
    ruleId: 'CLINICAL_TRIAL_REFERENCES',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Clinical Evidence',
    description: 'Update clinical trial references to include European studies',
    rationale: 'French regulatory requirements emphasize European clinical data',
    exampleBefore: 'Based on pivotal US trials (SOLO 1, SOLO 2)',
    exampleAfter: 'Basé sur études européennes (SOLO 1, SOLO 2, CHRONOS)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-005',
    ruleId: 'DATE_FORMAT_CHANGE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Formatting Standards',
    description: 'Change date format from MM/DD/YYYY to DD/MM/YYYY',
    rationale: 'French standard date format uses DD/MM/YYYY',
    exampleBefore: '03/15/2024',
    exampleAfter: '15/03/2024',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-006',
    ruleId: 'PRESCRIBING_INFO_REPLACEMENT',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Regulatory Documentation',
    description: 'Replace US PI with French RCP',
    rationale: 'French market requires RCP (Résumé des Caractéristiques du Produit)',
    exampleBefore: 'See Full Prescribing Information',
    exampleAfter: 'Voir le RCP complet',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-007',
    ruleId: 'PHARMACOVIGILANCE_UPDATE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Safety Reporting',
    description: 'Update adverse event reporting for French pharmacovigilance',
    rationale: 'France follows EMA pharmacovigilance and ANSM reporting',
    exampleBefore: 'Report adverse events to FDA',
    exampleAfter: 'Déclarer les effets indésirables à l\'ANSM',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-008',
    ruleId: 'PROFESSIONAL_SOCIETIES',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Professional References',
    description: 'Include French dermatology societies (SFD)',
    rationale: 'French healthcare values SFD guidelines',
    exampleBefore: 'Recommended by American Academy of Dermatology',
    exampleAfter: 'Recommandé par la SFD',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-009',
    ruleId: 'WEBSITE_DOMAIN_UPDATE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Digital Presence',
    description: 'Replace US URLs with French .fr domain',
    rationale: 'French HCPs expect localized French website',
    exampleBefore: 'Visit www.dupixent.com',
    exampleAfter: 'Visitez www.dupixent.fr',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-must-010',
    ruleId: 'REIMBURSEMENT_LANGUAGE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Healthcare System',
    description: 'Update for French social security (ALD coverage)',
    rationale: 'France has Sécurité Sociale with ALD coverage',
    exampleBefore: 'Covered by most insurance plans',
    exampleAfter: 'Prise en charge Sécurité Sociale (ALD)',
    therapeuticArea: 'Immunology'
  },

  // CANNOT_CHANGE Rules (10)
  {
    id: 'dup-us-fr-cannot-001',
    ruleId: 'MECHANISM_OF_ACTION',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Mechanism of Action',
    description: 'IL-4 and IL-13 dual pathway inhibition',
    rationale: 'Core mechanism scientifically established',
    exampleBefore: 'Dupilumab inhibits IL-4 and IL-13',
    exampleAfter: 'Dupilumab inhibe IL-4 et IL-13 (traduction uniquement)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-002',
    ruleId: 'PRIMARY_INDICATION',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Approved Indication',
    description: 'Moderate-to-severe atopic dermatitis indication',
    rationale: 'EMA-approved indication identical to FDA',
    exampleBefore: 'Indicated for moderate-to-severe AD',
    exampleAfter: 'Indiqué pour DA modérée à sévère (même indication)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-003',
    ruleId: 'STANDARD_DOSING',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Dosing',
    description: 'Standard dosing (600mg loading, 300mg Q2W)',
    rationale: 'Approved dosing identical across FDA and EMA',
    exampleBefore: '600mg loading, then 300mg Q2W',
    exampleAfter: '600mg puis 300mg Q2W (même posologie)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-004',
    ruleId: 'CLINICAL_EFFICACY_DATA',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Clinical Evidence',
    description: 'Pivotal trial outcomes (EASI-75, IGA 0/1)',
    rationale: 'Clinical trial results scientifically validated',
    exampleBefore: 'EASI-75 in 51% (SOLO 1)',
    exampleAfter: 'EASI-75 chez 51% (SOLO 1) (mêmes données)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-005',
    ruleId: 'ADVERSE_EVENT_PROFILE',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Safety Profile',
    description: 'Core AE profile (injection reactions, conjunctivitis)',
    rationale: 'Safety data universal',
    exampleBefore: 'Injection reactions (10%), conjunctivitis (10%)',
    exampleAfter: 'Réactions injection (10%), conjonctivite (10%) (mêmes données)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-006',
    ruleId: 'CONTRAINDICATIONS',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Contraindications',
    description: 'Hypersensitivity to dupilumab',
    rationale: 'Contraindications medically absolute',
    exampleBefore: 'Contraindicated if hypersensitive',
    exampleAfter: 'Contre-indiqué si hypersensible (même)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-007',
    ruleId: 'BIOMARKER_MONITORING',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Monitoring Requirements',
    description: 'Eosinophil monitoring in asthma',
    rationale: 'Clinical monitoring based on safety data',
    exampleBefore: 'Monitor eosinophils in asthma',
    exampleAfter: 'Surveiller éosinophiles (même exigence)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-008',
    ruleId: 'DRUG_INTERACTIONS',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Drug Interactions',
    description: 'No significant drug interactions',
    rationale: 'PK data scientifically established',
    exampleBefore: 'No clinically significant interactions',
    exampleAfter: 'Aucune interaction significative (mêmes données)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-009',
    ruleId: 'PREGNANCY_CATEGORY',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Special Populations',
    description: 'Pregnancy safety data',
    rationale: 'Limited pregnancy data requires consistent messaging',
    exampleBefore: 'Limited data in pregnancy',
    exampleAfter: 'Données limitées grossesse (même)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-cannot-010',
    ruleId: 'MOLECULAR_STRUCTURE',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Pharmacology',
    description: 'Monoclonal antibody structure (IgG4)',
    rationale: 'Chemical structure universal',
    exampleBefore: 'Fully human mAb (IgG4)',
    exampleAfter: 'mAb humain (IgG4) (même structure)',
    therapeuticArea: 'Immunology'
  },

  // SHOULD_CHANGE Rules (10)
  {
    id: 'dup-us-fr-should-001',
    ruleId: 'FORMAL_COMMUNICATION',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Communication Tone',
    description: 'Use formal French "vous" form',
    rationale: 'French medical communication requires formal address',
    exampleBefore: 'Talk to your doctor',
    exampleAfter: 'Parlez-en à votre médecin (vous formel)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-002',
    ruleId: 'EVIDENCE_BASED_EMPHASIS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Medical Culture',
    description: 'Emphasize HAS recommendations',
    rationale: 'French culture values HAS guidelines',
    exampleBefore: 'Proven effective',
    exampleAfter: 'Efficacité selon recommandations HAS',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-003',
    ruleId: 'BIOLOGICS_EXPERTISE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Treatment Context',
    description: 'Reference French biologics pathways',
    rationale: 'France has specific biologics prescription requirements',
    exampleBefore: 'Available by prescription',
    exampleAfter: 'Prescription initiale hospitalière',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-004',
    ruleId: 'QUALITY_OF_LIFE_MEASURES',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Patient Outcomes',
    description: 'Use French-validated QoL instruments',
    rationale: 'French healthcare emphasizes French QoL measures',
    exampleBefore: 'Improves quality of life',
    exampleAfter: 'Améliore QdV (DLQI français)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-005',
    ruleId: 'PATIENT_SUPPORT_PROGRAMS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Patient Services',
    description: 'Adapt patient support for French context',
    rationale: 'French patient programs differ from US',
    exampleBefore: 'MyDupixent support',
    exampleAfter: 'Programme accompagnement Dupixent',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-006',
    ruleId: 'MULTIDISCIPLINARY_CARE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Care Delivery',
    description: 'Emphasize French multidisciplinary model',
    rationale: 'French healthcare values coordinated care',
    exampleBefore: 'Consult dermatologist',
    exampleAfter: 'Prise en charge multidisciplinaire',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-007',
    ruleId: 'LONG_TERM_THERAPY_EMPHASIS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Treatment Duration',
    description: 'Emphasize long-term control',
    rationale: 'French reimbursement values sustained efficacy',
    exampleBefore: 'Rapid improvement',
    exampleAfter: 'Contrôle durable 52 semaines',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-008',
    ruleId: 'IMMUNIZATION_GUIDANCE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Preventive Care',
    description: 'Include French vaccination recommendations',
    rationale: 'French vaccination guidelines for biologics',
    exampleBefore: 'Discuss vaccinations',
    exampleAfter: 'Vérifier vaccins (calendrier français)',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-009',
    ruleId: 'COST_EFFECTIVENESS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Health Economics',
    description: 'Include HAS health economic evaluation',
    rationale: 'French system values HAS assessments',
    exampleBefore: 'Effective treatment',
    exampleAfter: 'Évaluation médico-économique HAS favorable',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-fr-should-010',
    ruleId: 'PEDIATRIC_EXPERIENCE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'France',
    category: 'Pediatric Use',
    description: 'Reference French pediatric networks',
    rationale: 'France has established pediatric dermatology',
    exampleBefore: 'Safe for children 6mo+',
    exampleAfter: 'Enfants 6mo+ sous surveillance pédiatrique',
    therapeuticArea: 'Immunology'
  },

  // ============================================================
  // US → CHINA (CN) - 30 Rules (10 MUST + 10 CANNOT + 10 SHOULD)
  // ============================================================
  
  // MUST_CHANGE Rules (10)
  {
    id: 'dup-us-cn-must-001',
    ruleId: 'REG_BODY_REPLACEMENT',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Regulatory Authority',
    description: 'Replace FDA with NMPA',
    rationale: 'China operates under NMPA regulatory authority',
    exampleBefore: 'FDA-approved',
    exampleAfter: 'NMPA批准',
    regulatoryReference: 'NMPA',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-002',
    ruleId: 'MEDICAL_TERMINOLOGY_TRANSLATION',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Language & Terminology',
    description: 'Translate to Simplified Chinese',
    rationale: 'Chinese HCPs require Simplified Chinese',
    exampleBefore: 'Moderate-to-severe atopic dermatitis',
    exampleAfter: '中重度特应性皮炎',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-003',
    ruleId: 'CONTACT_INFO_LOCALIZATION',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Contact Information',
    description: 'Replace with Chinese hotline',
    rationale: 'Chinese HCPs need Mandarin support',
    exampleBefore: '1-800-DUPIXENT',
    exampleAfter: '400-820-0266',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-004',
    ruleId: 'CLINICAL_TRIAL_REFERENCES',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Clinical Evidence',
    description: 'Include Chinese clinical data',
    rationale: 'Chinese regulations require local data',
    exampleBefore: 'Based on US trials',
    exampleAfter: '基于全球及中国临床研究',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-005',
    ruleId: 'DATE_FORMAT_CHANGE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Formatting Standards',
    description: 'Change to YYYY-MM-DD format',
    rationale: 'Chinese standard uses ISO 8601',
    exampleBefore: '03/15/2024',
    exampleAfter: '2024-03-15',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-006',
    ruleId: 'PRESCRIBING_INFO_REPLACEMENT',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Regulatory Documentation',
    description: 'Replace with Chinese product insert (说明书)',
    rationale: 'China requires NMPA-approved insert',
    exampleBefore: 'See Prescribing Information',
    exampleAfter: '请参阅说明书',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-007',
    ruleId: 'PHARMACOVIGILANCE_UPDATE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Safety Reporting',
    description: 'Update for Chinese pharmacovigilance',
    rationale: 'China has NMPA reporting requirements',
    exampleBefore: 'Report to FDA',
    exampleAfter: '向NMPA报告不良反应',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-008',
    ruleId: 'PROFESSIONAL_SOCIETIES',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Professional References',
    description: 'Include Chinese dermatology associations',
    rationale: 'Chinese system values CDA guidelines',
    exampleBefore: 'AAD recommendations',
    exampleAfter: '中华医学会皮肤科学分会指南',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-009',
    ruleId: 'WEBSITE_DOMAIN_UPDATE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Digital Presence',
    description: 'Replace with Chinese .cn domain',
    rationale: 'Chinese HCPs expect local website',
    exampleBefore: 'www.dupixent.com',
    exampleAfter: 'www.dupixent.com.cn',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-must-010',
    ruleId: 'REIMBURSEMENT_LANGUAGE',
    ruleType: 'MUST_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Healthcare System',
    description: 'Update for NRDL system',
    rationale: 'China operates on NRDL reimbursement',
    exampleBefore: 'Insurance coverage',
    exampleAfter: '纳入医保目录',
    therapeuticArea: 'Immunology'
  },

  // CANNOT_CHANGE Rules (10)
  {
    id: 'dup-us-cn-cannot-001',
    ruleId: 'MECHANISM_OF_ACTION',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Mechanism of Action',
    description: 'IL-4/IL-13 inhibition',
    rationale: 'Core mechanism scientifically established',
    exampleBefore: 'Inhibits IL-4 and IL-13',
    exampleAfter: '抑制IL-4和IL-13（仅翻译）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-002',
    ruleId: 'PRIMARY_INDICATION',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Approved Indication',
    description: 'AD indication',
    rationale: 'NMPA-approved indication',
    exampleBefore: 'For moderate-to-severe AD',
    exampleAfter: '中重度AD（相同适应症）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-003',
    ruleId: 'STANDARD_DOSING',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Dosing',
    description: 'Dosing regimen',
    rationale: 'NMPA-approved dosing',
    exampleBefore: '600mg then 300mg Q2W',
    exampleAfter: '600mg后300mg Q2W（相同）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-004',
    ruleId: 'CLINICAL_EFFICACY_DATA',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Clinical Evidence',
    description: 'Efficacy outcomes',
    rationale: 'Trial results scientifically validated',
    exampleBefore: 'EASI-75 in 51%',
    exampleAfter: 'EASI-75达51%（相同数据）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-005',
    ruleId: 'ADVERSE_EVENT_PROFILE',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Safety Profile',
    description: 'AE profile',
    rationale: 'Safety data universal',
    exampleBefore: 'Injection reactions 10%',
    exampleAfter: '注射反应10%（相同）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-006',
    ruleId: 'CONTRAINDICATIONS',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Contraindications',
    description: 'Hypersensitivity',
    rationale: 'Contraindications absolute',
    exampleBefore: 'CI if hypersensitive',
    exampleAfter: '过敏禁用（相同）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-007',
    ruleId: 'BIOMARKER_MONITORING',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Monitoring Requirements',
    description: 'Eosinophil monitoring',
    rationale: 'Monitoring based on safety',
    exampleBefore: 'Monitor eosinophils',
    exampleAfter: '监测嗜酸性粒细胞（相同）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-008',
    ruleId: 'DRUG_INTERACTIONS',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Drug Interactions',
    description: 'No significant interactions',
    rationale: 'PK data established',
    exampleBefore: 'No significant interactions',
    exampleAfter: '无显著相互作用（相同）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-009',
    ruleId: 'PREGNANCY_CATEGORY',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Special Populations',
    description: 'Pregnancy data',
    rationale: 'Consistent pregnancy messaging',
    exampleBefore: 'Limited pregnancy data',
    exampleAfter: '孕妇数据有限（相同）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-cannot-010',
    ruleId: 'MOLECULAR_STRUCTURE',
    ruleType: 'CANNOT_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Pharmacology',
    description: 'mAb structure',
    rationale: 'Chemical structure universal',
    exampleBefore: 'Human mAb IgG4',
    exampleAfter: '人单抗IgG4（相同）',
    therapeuticArea: 'Immunology'
  },

  // SHOULD_CHANGE Rules (10)
  {
    id: 'dup-us-cn-should-001',
    ruleId: 'FORMAL_COMMUNICATION',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Communication Tone',
    description: 'Use formal Chinese',
    rationale: 'Chinese medical communication formal',
    exampleBefore: 'Talk to doctor',
    exampleAfter: '请咨询医生',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-002',
    ruleId: 'EVIDENCE_BASED_EMPHASIS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Medical Culture',
    description: 'Emphasize Chinese guidelines',
    rationale: 'Chinese culture values CMA guidelines',
    exampleBefore: 'Proven effective',
    exampleAfter: '符合中华医学会指南',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-003',
    ruleId: 'BIOLOGICS_EXPERTISE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Treatment Context',
    description: 'Reference Chinese biologics pathways',
    rationale: 'China has tertiary hospital requirements',
    exampleBefore: 'By prescription',
    exampleAfter: '需专科医生处方',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-004',
    ruleId: 'QUALITY_OF_LIFE_MEASURES',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Patient Outcomes',
    description: 'Use Chinese-validated QoL',
    rationale: 'Chinese healthcare uses Chinese QoL',
    exampleBefore: 'Improves QoL',
    exampleAfter: '改善生活质量（中文版DLQI）',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-005',
    ruleId: 'PATIENT_SUPPORT_PROGRAMS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Patient Services',
    description: 'Adapt for Chinese context',
    rationale: 'Chinese patient programs differ',
    exampleBefore: 'MyDupixent support',
    exampleAfter: 'Dupixent患者关爱项目',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-006',
    ruleId: 'MULTIDISCIPLINARY_CARE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Care Delivery',
    description: 'Emphasize Chinese MDT model',
    rationale: 'Chinese healthcare values specialist consultation',
    exampleBefore: 'Consult dermatologist',
    exampleAfter: '建议多学科会诊',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-007',
    ruleId: 'LONG_TERM_THERAPY_EMPHASIS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Treatment Duration',
    description: 'Emphasize sustained efficacy',
    rationale: 'Chinese healthcare values long-term outcomes',
    exampleBefore: 'Rapid improvement',
    exampleAfter: '52周持续疗效',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-008',
    ruleId: 'IMMUNIZATION_GUIDANCE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Preventive Care',
    description: 'Include Chinese vaccination guidance',
    rationale: 'Chinese vaccination guidelines',
    exampleBefore: 'Discuss vaccinations',
    exampleAfter: '按中国免疫规划评估',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-009',
    ruleId: 'COST_EFFECTIVENESS',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Health Economics',
    description: 'Include Chinese health economics',
    rationale: 'Chinese system values cost-effectiveness',
    exampleBefore: 'Effective treatment',
    exampleAfter: '具成本效益',
    therapeuticArea: 'Immunology'
  },
  {
    id: 'dup-us-cn-should-010',
    ruleId: 'PEDIATRIC_EXPERIENCE',
    ruleType: 'SHOULD_CHANGE',
    sourceMarket: 'US',
    targetMarket: 'China',
    category: 'Pediatric Use',
    description: 'Reference Chinese pediatric networks',
    rationale: 'China has pediatric dermatology in major hospitals',
    exampleBefore: 'Safe for children 6mo+',
    exampleAfter: '6月龄+儿童需儿科监护',
    therapeuticArea: 'Immunology'
  }
];

// Helper functions for Dupixent regulatory rules

export function getDupixentRules(sourceMarket, targetMarket) {
  return DupixentRegulatoryRules.filter(
    rule => rule.sourceMarket === sourceMarket && rule.targetMarket === targetMarket
  );
}

export function getDupixentRulesByType(
  sourceMarket, 
  targetMarket, 
  ruleType
) {
  return DupixentRegulatoryRules.filter(
    rule => 
      rule.sourceMarket === sourceMarket && 
      rule.targetMarket === targetMarket && 
      rule.ruleType === ruleType
  );
}

export function convertDupixentRulesToMatrixEntries(rules) {
  return rules.map(rule => ({
    market: rule.targetMarket,
    therapeuticArea: rule.therapeuticArea,
    ruleCategory: rule.category,
    ruleId: rule.ruleId,
    ruleName: rule.description,
    changeRequirement: rule.ruleType,
    description: rule.description,
    rationale: rule.rationale,
    riskLevel: (rule.ruleType === 'MUST_CHANGE' ? 'high' : 
               rule.ruleType === 'CANNOT_CHANGE' ? 'critical' : 'medium'),
    validationMethod: (rule.ruleType === 'MUST_CHANGE' ? 'automated' : 'expert_review'),
    exampleTransformation: rule.exampleBefore && rule.exampleAfter ? {
      before: rule.exampleBefore,
      after: rule.exampleAfter,
      rationale: rule.rationale
    } : undefined
  }));
}